Patents Assigned to AGY Therapeutics, Inc.
  • Publication number: 20100256162
    Abstract: Compounds of general formula (I) in which R1, m, X, n, Y and R3 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.
    Type: Application
    Filed: October 10, 2006
    Publication date: October 7, 2010
    Applicant: AGY THERAPEUTICS, INC.
    Inventor: Connie L Sun
  • Patent number: 7060275
    Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTP?) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTP?, PTP? SM1 and PTP? SM2.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: June 13, 2006
    Assignee: AGY Therapeutics, Inc.
    Inventors: Sabine Mueller, Thorsten Melcher, Daniel Chin
  • Patent number: 7014838
    Abstract: The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents, which specifically bind to one or more of the identified brain tumor protein targets. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: March 21, 2006
    Assignee: AGY Therapeutics, Inc.
    Inventors: Sabine Mueller, Mirella Gonzalez-Zulueta, Erik Foehr, Daniel J. Chin
  • Patent number: 6977142
    Abstract: Methods for performing an end-point assay of protein disulfide isomerase activity. The method may be based on the enzyme-catalyzed reduction of insulin in the presence of dithiothreitol; measuring the aggregation of reduced insulin chains at 650 nm; and using hydrogen peroxide as a stop reagent.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: December 20, 2005
    Assignee: AGY Therapeutics, Inc.
    Inventors: Shu-Gui Huang, Donna Oksenberg, Roman Urfer
  • Patent number: 6924109
    Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilize RNA interference techniques in the validation process.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: August 2, 2005
    Assignee: AGY Therapeutics, Inc.
    Inventors: Thorsten Melcher, Keith Charles McFarland, Li Gan, Shiming Ye, Mirella Gonzalez-Zulueta
  • Patent number: 6876930
    Abstract: There is a pressing need for computer-implemented tools that can summarize and present the enormous amounts of public literature to facilitate analysis of gene expression data. The present invention provides techniques and systems for efficiently integrating public literature regarding gene function with data from gene expression profiling experiments. Information from literature databases relating to a particular set of DNA sequences of known expression pattern is retrieved, processed, cross-referenced and viewed to provide further information about a particular DNA sequence to facilitate its identification as a candidate gene.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: April 5, 2005
    Assignee: AGY Therapeutics, Inc.
    Inventors: Joseph Murray, Donna Hendrix, Daniel J Chin
  • Patent number: 6846641
    Abstract: A tissue culture model of oxygen/glucose deprivation induced cell death is provided, which is useful in the analysis of the mechanisms of cell death following brain ischemia, and for screening anti-ischemic drugs. By adopting the in vivo concentrations of calcium, potassium and hydrogen ions to the incubation medium a model is established that shows conspicuous similarities with the temporal and special development of cell death in vivo: selective and delayed CA1 damage, a damage mitigated by blockade of the NMDA and AMPA receptors, and a striking augmentation of damage by high levels of glucose.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: January 25, 2005
    Assignee: AGY Therapeutics, Inc.
    Inventors: Tadeusz Wieloch, Anna Rytter, Tobias Cronberg
  • Patent number: 6841351
    Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilized RNA interference techniques in the validation process.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: January 11, 2005
    Assignee: AGY Therapeutics, Inc.
    Inventors: Li Gan, Mirella Gonzalez-Zulueta, Kristin Anton, Richa Wilson, Thorsten Melcher, Daniel Chin
  • Patent number: 6670138
    Abstract: The present invention identifies a gene whose gene product provides a protective effect against neurological disorders or neuronal injuries. Further, the invention provides methods for diagnosing or assessing an individual's susceptibility to a neuronal injury such as stroke. Also provided are therapeutic methods for treating patients, and methods for prophylactically treating individuals susceptible to various neurological disorders or neuronal injuries. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered or are at risk to suffer such disorders or injuries.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: December 30, 2003
    Assignee: AGY Therapeutics, Inc.
    Inventors: Mirella Gonzalez-Zulueta, Mehrdad Shamloo, K.C. McFarland, Daniel Chin, Tadeusz Wieloch, Thorsten Melcher
  • Patent number: 6660483
    Abstract: The invention relates to a human phospholipase C expressed in the brain (B-PLC) and induced in response to ischemic brain tissue. The inventions provides methods and reagents useful for diagnosis and treatment of hypoxic-ischemic brain insult such as stroke.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: December 9, 2003
    Assignee: AGY Therapeutics, Inc.
    Inventors: Kalev Kask, Thorsten Melcher, Daniel J. Chin
  • Patent number: 6586239
    Abstract: A method is provided for obtaining a cell population enriched in microglial cells by contacting a composition containing microglial cells with immunoglobulin immobilized on a matrix such as a polystyrene matrix before or after contact with the cells, allowing the cells to bind to the with immunoglobulin, and removing non-adherent cells to obtain a cell population containing preferably at least 95% microglial cells. The immunoglobulin may be Fc domain-containing immunoglobulin G, and Fc receptors of the microglial cells bind to the Fc domain of immunoglobulin G. Purified Fc fragments from immunoglobulin G may be used in place of immunoglobulin G. The microglial cells may be from brain tissue, and from tissue of a normal animal or tissue of an animal having a neurological disorder.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: July 1, 2003
    Assignee: AGY Therapeutics, Inc.
    Inventors: Huaiyu Mi, Saili Yi
  • Publication number: 20030054394
    Abstract: Techniques for facilitating the identification of candidate genes from a plurality of DNA sequences. According to an embodiment of the present invention, techniques are provided for extracting and integrating information from various information sources and results of various analyses, and storing the integrated information in a form which is conducive to identification of candidate genes. The stored information may include results of a homology search for the plurality of DNA sequences, annotative information for the plurality of DNA sequences indicating the biochemical functions and physiological roles of the plurality of DNA sequences, gene expression profile data for the plurality of DNA sequences describing behavioral patterns of the plurality of DNA sequences, results from clustering the plurality of DNA sequences based on time course data as described by the gene expression profile data, and other information.
    Type: Application
    Filed: August 27, 2002
    Publication date: March 20, 2003
    Applicant: AGY Therapeutics, Inc.
    Inventors: Daniel J. Chin, Donna Hendrix, Oliver Zhao
  • Patent number: 6521414
    Abstract: The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTPL1 agonist or antagonist that modulates NMDA-R signaling. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling. The present invention further provides methods for isolating PTPL1 from a biological preparation.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: February 18, 2003
    Assignee: AGY Therapeutics, Inc.
    Inventors: Thorsten Melcher, Kalev Kask
  • Publication number: 20030027168
    Abstract: Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilized RNA interference techniques in the validation process.
    Type: Application
    Filed: October 19, 2001
    Publication date: February 6, 2003
    Applicant: AGY Therapeutics, Inc.
    Inventors: Li Gan, Mirella Gonzalez-Zulueta, Kristin Anton, Richa Wilson, Thorsten Melcher, Daniel Chin
  • Publication number: 20020172958
    Abstract: The present invention identifies a gene whose gene product provides a protective effect against neurological disorders or neuronal injuries. Further, the invention provides methods for diagnosing or assessing an individual's susceptibility to a neuronal injury such as stroke. Also provided are therapeutic methods for treating patients, and methods for prophylactically treating individuals susceptible to various neurological disorders or neuronal injuries. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered or are at risk to suffer such disorders or injuries.
    Type: Application
    Filed: October 31, 2001
    Publication date: November 21, 2002
    Applicant: AGY Therapeutics, Inc.
    Inventors: Mirella Gonzalez-Zulueta, Mehrdad Shamloo, K.C. McFarland, Daniel Chin, Tadeusz Wieloch, Thorsten Melcher
  • Patent number: 6470277
    Abstract: Techniques for facilitating the identification of candidate genes from a plurality of DNA sequences. According to an embodiment of the present invention, techniques are provided for extracting and integrating information from various information sources and results of various analyses, and storing the integrated information in a form which is conducive to identification of candidate genes. The stored information may include results of a homology search for the plurality of DNA sequences, annotative information for the plurality of DNA sequences indicating the biochemical functions and physiological roles of the plurality of DNA sequences, gene expression profile data for the plurality of DNA sequences describing behavioral patterns of the plurality of DNA sequences, results from clustering the plurality of DNA sequences based on time course data as described by the gene expression profile data, and other information.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: October 22, 2002
    Assignee: AGY Therapeutics, Inc.
    Inventors: Daniel J. Chin, Donna Hendrix, Oliver Zhao
  • Patent number: 6455026
    Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents that specifically bind to human protein tyrosine phosphatase-zeta (PTP&zgr;) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: September 24, 2002
    Assignee: AGY Therapeutics, Inc.
    Inventors: Sabine Mueller, Thorsten Melcher, Daniel J. Chin